NCYT - NOVACYT SA - Share Chat

Novacyt SA is a clinical diagnostics company, dual-listed on the London Stock Exchange’s AIM market and Euronext Growth Paris. Specialising in molecular diagnostics, the company designs, develops, manufactures, and commercialises in vitro diagnostic products across various disease areas.

Novacyt gained significant market attention and revenue during the COVID-19 pandemic, becoming a key supplier of PCR diagnostic tests. Post-pandemic, the company has faced considerable challenges, experiencing a substantial decline in COVID-related sales. Its current strategic focus is on diversifying its core diagnostics portfolio into areas such as oncology, infectious diseases, and reproductive health, alongside stringent cost management. The company aims to rebuild a sustainable business following the unique demand seen during the pandemic, operating through subsidiaries like Primerdesign.